Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation and dose-expansion study of HB0028 in advanced solid tumors
CTR20222004Phase 2Active
- Sponsor
- Huabo Biopharm
- Start
- Oct 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HB0028 in Nonhematologic neoplasms, Cervical Cancer (CC), sponsored by Huabo Biopharm. Started Oct 2022; status: active.
02
Drugs
HB0028
03
Conditions
Nonhematologic neoplasmsCervical Cancer (CC)
Beyond the preview
Go deeper on CTR20222004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222004.